A non-intoxicating molecule the brain takes seriously.
Cannabidivarin — CBDV — is a quieter, less-studied cousin of CBD. It comes from the same plant, works differently in the brain, and does not cause a high. For most of cannabis-research history, almost nobody paid it any attention.
CBDV and CBD are close chemical cousins, but they are not the same. The differences between them are enough that CBDV acts on different parts of the brain than CBD — which is why it has different effects.
That changed when scientists started noticing something specific: in autistic children — and in animal studies of related conditions like Fragile X and Rett syndrome — CBDV seemed to do more than just calm or sedate. It seemed to gently steady the brain itself, not knock a child out. The kind of effect that, if it holds up in the larger trials underway now, could mean fewer rages and meltdowns, more flexibility, less anxiety — and without the heavy side effects of the medications currently prescribed.
This site collects what the published research has shown so far — what's been tested, where the findings agree, and where the evidence honestly stops. The goal is to give a clear picture of what we know — and what we don't — without overselling anything.
What the science is starting to show.
A $1.3M clinical trial in autistic children is underway right now. Brain-imaging studies in autistic adults have already shown that CBDV moves the brain toward more typical patterns — gently, not by sedating it. And three separate animal studies — for autism, Fragile X, and Rett syndrome — have all pointed at the same conclusion.
The most-watched study in this space is the one shown below. It's the first direct test of whether CBDV could meaningfully help with the day-to-day struggles that bring families to a doctor in the first place — outbursts, aggression, self-injury — without the heavy side effects (weight gain, drowsiness, metabolic problems) of the medications currently available.
The endocannabinoid system, in one paragraph.
Your body has its own internal version of a cannabis-like signaling system, even if you've never been near the plant. It quietly helps regulate mood, the urge to socialize, inflammation, and memory — running in the background of every ordinary day. In autistic children, this system runs measurably quieter — a finding two separate research labs in two countries have now confirmed.
This is the most important piece of context for understanding why CBDV is being seriously studied in autism. CBDV doesn't act on a generic system — it acts on the specific one that, in autistic children, is running differently from typical. Treating it isn't a guess. It's a direct response to a real, measurable difference.
Translating evidence honestly.
Autism is not a single condition with a single cause, and CBDV will not be a single cure. The Center exists in the gap between the research that's been done and the families who need to read it.
For families currently caught between heavy psychiatric medications — the kind that calm a child by sedating them — and no medical help at all, a compound that gently steadies the brain without causing a high is a meaningful new direction. One that deserves to be reported plainly, without hype.Who we are, and how we work →